11 Citations (Scopus)

Abstract

The rapidly emerging technology of synthetic biology will place great strain upon the extant regulatory system due to three atypical characteristics of this nascent technology: (1) synthetic biology organisms can evolve; (2) traditional risk structures do not apply; and (3) the conventional regulatory focus on end-products may be a poor match for novel organisms that produce products. This Article presents one of the first assessments of the regulatory and oversight challenges produced by the beneficial application of synthetic biology, for energy, environmental, medical, and other purposes. Due to the uncertainty present at this early stage of synthetic biology development, and the practical political context, it is unlikely that the significant statutory and regulatory gaps identified herein could be cured directly. This Article recommends instead a selection of "soft law" alternatives that could more quickly provide flexible and adaptive measures to help fill regulatory gaps in a manner that allows this promising technology to develop as rapidly as possible, while still adequately guarding against risks to human health and the environment.

Original languageEnglish (US)
Pages (from-to)155-200
Number of pages46
JournalIowa Law Review
Volume100
Issue number1
StatePublished - Nov 1 2014

Fingerprint

biology
uncertainty
energy
Law
present
health

ASJC Scopus subject areas

  • Law

Cite this

The living regulatory challenges of synthetic biology. / Mandel, Gregory N.; Marchant, Gary.

In: Iowa Law Review, Vol. 100, No. 1, 01.11.2014, p. 155-200.

Research output: Contribution to journalArticle

Mandel, Gregory N. ; Marchant, Gary. / The living regulatory challenges of synthetic biology. In: Iowa Law Review. 2014 ; Vol. 100, No. 1. pp. 155-200.
@article{4ac71f552d1748708ad5bddaa854fdf5,
title = "The living regulatory challenges of synthetic biology",
abstract = "The rapidly emerging technology of synthetic biology will place great strain upon the extant regulatory system due to three atypical characteristics of this nascent technology: (1) synthetic biology organisms can evolve; (2) traditional risk structures do not apply; and (3) the conventional regulatory focus on end-products may be a poor match for novel organisms that produce products. This Article presents one of the first assessments of the regulatory and oversight challenges produced by the beneficial application of synthetic biology, for energy, environmental, medical, and other purposes. Due to the uncertainty present at this early stage of synthetic biology development, and the practical political context, it is unlikely that the significant statutory and regulatory gaps identified herein could be cured directly. This Article recommends instead a selection of {"}soft law{"} alternatives that could more quickly provide flexible and adaptive measures to help fill regulatory gaps in a manner that allows this promising technology to develop as rapidly as possible, while still adequately guarding against risks to human health and the environment.",
author = "Mandel, {Gregory N.} and Gary Marchant",
year = "2014",
month = "11",
day = "1",
language = "English (US)",
volume = "100",
pages = "155--200",
journal = "Iowa Law Review",
issn = "0021-0552",
publisher = "University of Iowa",
number = "1",

}

TY - JOUR

T1 - The living regulatory challenges of synthetic biology

AU - Mandel, Gregory N.

AU - Marchant, Gary

PY - 2014/11/1

Y1 - 2014/11/1

N2 - The rapidly emerging technology of synthetic biology will place great strain upon the extant regulatory system due to three atypical characteristics of this nascent technology: (1) synthetic biology organisms can evolve; (2) traditional risk structures do not apply; and (3) the conventional regulatory focus on end-products may be a poor match for novel organisms that produce products. This Article presents one of the first assessments of the regulatory and oversight challenges produced by the beneficial application of synthetic biology, for energy, environmental, medical, and other purposes. Due to the uncertainty present at this early stage of synthetic biology development, and the practical political context, it is unlikely that the significant statutory and regulatory gaps identified herein could be cured directly. This Article recommends instead a selection of "soft law" alternatives that could more quickly provide flexible and adaptive measures to help fill regulatory gaps in a manner that allows this promising technology to develop as rapidly as possible, while still adequately guarding against risks to human health and the environment.

AB - The rapidly emerging technology of synthetic biology will place great strain upon the extant regulatory system due to three atypical characteristics of this nascent technology: (1) synthetic biology organisms can evolve; (2) traditional risk structures do not apply; and (3) the conventional regulatory focus on end-products may be a poor match for novel organisms that produce products. This Article presents one of the first assessments of the regulatory and oversight challenges produced by the beneficial application of synthetic biology, for energy, environmental, medical, and other purposes. Due to the uncertainty present at this early stage of synthetic biology development, and the practical political context, it is unlikely that the significant statutory and regulatory gaps identified herein could be cured directly. This Article recommends instead a selection of "soft law" alternatives that could more quickly provide flexible and adaptive measures to help fill regulatory gaps in a manner that allows this promising technology to develop as rapidly as possible, while still adequately guarding against risks to human health and the environment.

UR - http://www.scopus.com/inward/record.url?scp=84918535499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918535499&partnerID=8YFLogxK

M3 - Article

VL - 100

SP - 155

EP - 200

JO - Iowa Law Review

JF - Iowa Law Review

SN - 0021-0552

IS - 1

ER -